Skip to main content

Osimertinib + Chemo Improves Progression-Free Survival in Advanced NSCLC

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 16, 2023.

By Elana Gotkine HealthDay Reporter

THURSDAY, Nov. 16, 2023 -- For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study published online Nov. 8 in the New England Journal of Medicine.

David Planchard, M.D., Ph.D., from Institut Gustave Roussy in Villejuif, France, and colleagues randomly assigned 557 patients with EGFR-mutated advanced NSCLC who had not previously received treatment for advanced disease to receive osimertinib (80 mg once daily) with chemotherapy (pemetrexed plus either cisplatin or carboplatin) or to receive osimertinib monotherapy (80 mg once daily) in a 1:1 ratio.

The researchers found that investigator-assessed PFS was significantly longer in the osimertinib-chemotherapy group versus the osimertinib group. Overall, 57 and 41 percent of patients in the osimertinib-chemotherapy group and osimertintib group, respectively, were alive and progression-free at 24 months. Consistent with the primary analysis, PFS as assessed according to blinded independent review was significantly longer in the combination group. An objective (complete or partial) response was observed in 83 and 76 percent of patients in the osimertinib-chemotherapy and osimertinib groups; median response duration was 24.0 and 15.3 months, respectively. The combination group had a higher incidence of grade 3 or higher adverse events from any cause than the monotherapy group.

"Osimertinib plus chemotherapy with pemetrexed and a platinum-based agent significantly improved progression-free survival as compared with osimertinib alone in the context of first-line treatment of patients with EGFR-mutated advanced NSCLC," the authors write.

Several authors disclosed ties to AstraZeneca, which manufactures osimertinib and funded the study.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer

MONDAY, April 22, 2024 -- The U.S. Food and Drug Administration has approved Alecensa (alectinib) as adjuvant treatment following tumor resection in patients with anaplastic...

Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer

FRIDAY, April 12, 2024 -- Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung...

Tislelizumab Plus Chemotherapy Beneficial for Resectable NSCLC

FRIDAY, Feb. 23, 2024 -- For patients with resectable non-small cell lung cancer (NSCLC), neoadjuvant tislelizumab (TIS) plus chemotherapy with adjuvant TIS yields significant...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.